e-learning
resources
Munich 2014
Sunday, 07.09.2014
Asthma and COPD devices and treatments
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
E. Marquez-Martin, F. Ortega Ruiz, E. Campano, C. De la Horra, J. M. Varela, E. Calderón (Seville, Spain)
Source:
International Congress 2014 – Asthma and COPD devices and treatments
Session:
Asthma and COPD devices and treatments
Session type:
Thematic Poster Session
Number:
926
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
E. Marquez-Martin, F. Ortega Ruiz, E. Campano, C. De la Horra, J. M. Varela, E. Calderón (Seville, Spain). Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD. Eur Respir J 2014; 44: Suppl. 58, 926
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatics
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Inflammation in COPD patients before and after roflumilast treatment
Source: International Congress 2014 – Asthma and COPD devices and treatments
Year: 2014
Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Experience of application the selective phosphodiesterase-4 inhibitor roflumilast in the patient with COPD and the metabolic syndrome
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Additive anti-inflammatory effect of glucocorticoids and PDE4 inhibitors on COPD CD8 cells
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014
A novel inhaled PI3Kδ inhibitor, LAS194223 reduces allergen-induced airway inflammation in rat
Source: International Congress 2014 – New drugs for asthma, COPD and pulmonary fibrosis
Year: 2014
Effect of roflumilast on airway remodeling in a murine model of chronic asthma
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015
Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
PPAR-alpha agonist (fenofibrate) therapy in exacerbation control of chronic obstructive pulmonary disease of severe stage
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014
Roflumilast N-oxide combined with PI3Kδ inhibitor improves the phenotype of early-onset COPD
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Safety of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis
Source: Annual Congress 2009 - Treatment of COPD
Year: 2009
Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD
Source: International Congress 2014 – Translational studies in COPD
Year: 2014
A prospective study of the effect of carbocysteine lysine salt on COPD exacerbations with or without inhaled steroids
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
In vitro
profile of the new inhaled pan-JAK inhibitor LAS194046
Source: International Congress 2014 – New treatments for cough, asthma, COPD and ILDs
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept